MOD-GRF 1-29 vs CJC-1295: GHRH Analog Research Comparison

# MOD-GRF 1-29 vs CJC-1295: GHRH Analog Research Comparison

References

• •PMID: 42694310
• •PMID: 42538058
• •PMID: 42395176

> Research Use Only (RUO) Disclaimer: MOD-GRF 1-29 and CJC-1295 are research peptides not approved for human use by the FDA. This article is for educational and informational purposes only and does not constitute medical advice.

MOD-GRF 1-29 and CJC-1295 are both synthetic analogs of growth hormone-releasing hormone (GHRH), yet they represent fundamentally different approaches to stimulating growth hormone (GH) secretion in research models. The critical distinction comes down to a single structural modification: the Drug Affinity Complex (DAC). Understanding this difference is essential for designing GH-axis studies with precision.

Overview: Two Analogs, One Receptor

Both peptides target the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, triggering the synthesis and release of growth hormone. Their divergence lies entirely in pharmacokinetics — how long they remain active in circulation and what pattern of GH secretion they produce.

The naming confusion is common and worth addressing upfront: "CJC-1295 without DAC" is another name for MOD-GRF 1-29. "CJC-1295" alone almost always refers to the DAC-containing version. In the research literature, these are distinct compounds with meaningfully different biological profiles.

MOD-GRF 1-29: Pulsatile GHRH Stimulation

Structure and Stability

MOD-GRF 1-29 is a 29-amino acid synthetic analog of the natural GHRH(1-29) sequence, modified at four positions to resist enzymatic degradation by dipeptidyl peptidase IV (DPP-IV):

• •Position 2: Ala → D-Ala (DPP-IV cleavage resistance)
• •Position 8: Asn → Gln (oxidation resistance)
• •Position 15: Gly → Ala (conformational stability)
• •Position 27: Met → Nle (methionine oxidation resistance)

Natural GHRH has a plasma half-life of approximately 2–4 minutes due to rapid DPP-IV cleavage. These four substitutions extend MOD-GRF 1-29's half-life to approximately 30 minutes, long enough to reach the pituitary and trigger GH release, but short enough to produce discrete pulsatile secretion patterns.

Mechanism of Action

After subcutaneous administration, MOD-GRF 1-29 binds to GHRHR on anterior pituitary somatotrophs, activating adenylate cyclase via Gs protein coupling. This increases intracellular cyclic AMP (cAMP) and stimulates both GH synthesis and secretion. The resulting GH release mirrors the physiological pulsatile pattern — a discrete peak within 15–45 minutes post-injection, returning to baseline within 2–3 hours.

This pulsatility has important implications for receptor sensitivity. Research suggests that continuous GHRHR stimulation leads to receptor downregulation and decreased somatotroph responsiveness over time, whereas pulsatile stimulation — as MOD-GRF 1-29 provides — may better preserve the GH response across repeated administrations.

CJC-1295 (with DAC): Sustained GH-Axis Activation

Structure and Albumin Binding

CJC-1295 incorporates the same DPP-IV-resistant backbone as MOD-GRF 1-29 but adds one critical modification: a reactive maleimidoproprionic acid (MPA) group at Lys38 — the Drug Affinity Complex. After injection, this moiety forms a covalent bond with the free cysteine residues on circulating albumin, the most abundant plasma protein.

Albumin binding confers a dramatically extended half-life: 6–8 days in human studies. A single dose can maintain elevated GH and IGF-1 levels for up to two weeks, making weekly or twice-monthly injection schedules feasible in research protocols.

Mechanism of Action

CJC-1295 activates the GHRHR through the same cAMP pathway as MOD-GRF 1-29. Because it maintains sustained plasma concentrations, however, it produces continuous rather than pulsatile GHRHR stimulation. This leads to:

• •Prolonged, sustained GH secretion (rather than discrete peaks)
• •Persistent IGF-1 elevation lasting 9–11 days post-injection
• •Broader systemic metabolic effects than observed with short-acting GHRH analogs

Teichman et al. (2006) conducted the pivotal human Phase I/II trial of CJC-1295. In 64 healthy adults aged 21–61, a single subcutaneous injection produced a 2–10-fold increase in mean GH levels lasting 6 days, with IGF-1 increases of 1.5–3-fold persisting for 9–11 days — all at well-tolerated doses (PMID: 16352683).

Head-to-Head Comparison

Research Evidence

MOD-GRF 1-29 Evidence Base

Animal studies using GHRH knockout (GHRH-KO) mice confirm that short-acting GHRH analogs can normalize growth trajectory when administered in patterns mimicking physiological GH pulses — typically 2–4 times daily in rodent models. These data support MOD-GRF 1-29 as the physiologically relevant research tool for studies requiring preserved somatotroph pulse dynamics.

CJC-1295 Clinical Evidence

CJC-1295 has the most robust human clinical dataset of any GHRH analog. Key findings from Teichman et al. (2006):

• •Single-dose CJC-1295 (30–60 μg/kg subcutaneous) produced mean GH increases of 2–10× above baseline
• •IGF-1 rose 1.5–3× above baseline and remained elevated for 9–11 days
• •Pharmacodynamic effects scaled dose-dependently up to 60 μg/kg
• •No serious adverse events at tested doses; most common effects were transient flushing and headache (PMID: 16352683)

Research Application: Which GHRH Analog to Use?

When MOD-GRF 1-29 Is the Right Choice

MOD-GRF 1-29 is preferred for studies requiring:

1. Physiological GH pulse modeling — circadian GH rhythm studies, sleep-stage GH research, or somatotroph pulse dynamics

2. GHRH + GHRP combination protocols — pairing with ghrelin receptor agonists (e.g., Ipamorelin, GHRP-6) for synergistic GH pulse amplification

3. Long-term receptor sensitivity studies — where maintaining GHRHR responsiveness across repeated stimulations is critical

4. Acute intervention windows — where brief GH elevation is the endpoint, not sustained IGF-1 elevation

When CJC-1295 (DAC) Is the Right Choice

CJC-1295 is better suited for:

1. Sustained IGF-1 elevation studies — metabolic, bone density, body composition, or muscle mass research requiring weeks of elevated IGF-1

2. Low-frequency dosing protocols — logistically simpler in long-duration animal or clinical research models

3. GH deficiency models — where restoring systemic IGF-1 output over extended periods is the primary endpoint

4. Convenience in longer research windows — once-weekly dosing reduces experimental burden

Stack Potential in Research Protocols

MOD-GRF 1-29 is frequently combined with GH secretagogues in research settings. The GHRH + GHRP combination has strong mechanistic rationale: GHRH primes the somatotroph and extends the GH pulse window, while ghrelin receptor agonists (GHRPs) suppress somatostatin and directly amplify GH release. The two signals synergize at the pituitary level, producing GH peaks significantly larger than either compound alone.

CJC-1295, given its prolonged action, is sometimes used alongside short-acting GHRPs administered at the time of desired acute GH pulses — the DAC formulation provides the sustained baseline IGF-1 elevation while the GHRP drives periodic GH surges on top of it.

For researchers interested in growth hormone secretagogue combinations, the Peptide Stack Builder tool can help design multi-compound protocols.

Research Verdict

MOD-GRF 1-29 and CJC-1295 are complementary research tools rather than direct competitors. The choice is determined entirely by the study's temporal design:

• •For pulsatile, physiologically accurate GH research: MOD-GRF 1-29 provides short half-life, natural GH secretion kinetics, and better receptor sensitivity preservation
• •For sustained IGF-1 elevation, body composition, or convenience-focused protocols: CJC-1295 with DAC delivers extended hormonal action that would require multiple daily injections to replicate with shorter-acting analogs

The naming convention — where "CJC-1295" means the DAC version and "MOD-GRF 1-29" (or "CJC-1295 without DAC") means the short-acting version — is worth understanding before interpreting research literature, as conflation of the two is a common source of confusion in GH peptide research.

---

For more on growth hormone secretagogues, see the CJC-1295 research profile, the Ipamorelin dosage guide, and the GHRH Analogs Compared guide.

This article is for informational and educational purposes only. MOD-GRF 1-29 and CJC-1295 are not FDA-approved for human use. For research use only.